Atherogenic dyslipidemia—marked by high triglycerides, low HDL, and small dense LDL—often hides behind normal LDL cholesterol. This insulin-resistant lipid pattern predicts cardiovascular disease earlier and more accurately than LDL alone.

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly called fatty liver, is not a liver problem alone—it is a systemic marker of insulin resistance. Often silent for years, MASLD signals elevated cardiometabolic, cognitive, and longevity risk long before abnormal liver enzymes or diabetes appear.

Insulin resistance often develops years before diabetes, heart disease, or dementia are diagnosed. During this silent phase, metabolic dysfunction damages blood vessels, the brain, and cellular aging pathways. Understanding insulin resistance early allows for targeted intervention that can meaningfully reduce cardiovascular risk, cognitive decline, and accelerated biological aging.

Advanced glycation end products (AGEs) are biologically active compounds formed through non-enzymatic reactions between sugars and proteins, lipids, or nucleic acids. While AGE accumulation is a normal feature of aging, modern dietary patterns, insulin resistance, oxidative stress, and chronic hyperglycemia markedly accelerate their formation. Increasing evidence identifies AGEs as a central and under-recognized contributor to atherosclerotic cardiovascular disease (ASCVD) an